pregabalin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Post-Herpetic Neuralgia
Conditions
Post-Herpetic Neuralgia
Trial Timeline
Oct 1, 2004 → Jun 1, 2006
NCT ID
NCT00159666About pregabalin
pregabalin is a approved stage product being developed by Pfizer for Post-Herpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00159666. Target conditions include Post-Herpetic Neuralgia.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01773993 | Pre-clinical | Completed |
| NCT01603394 | Approved | Terminated |
| NCT01463306 | Phase 3 | Completed |
| NCT01298466 | Approved | Withdrawn |
| NCT01474772 | Phase 3 | Completed |
| NCT01397006 | Approved | Withdrawn |
| NCT01020526 | Approved | Completed |
| NCT01202227 | Phase 3 | Completed |
| NCT01226667 | Approved | Completed |
| NCT00819988 | Phase 3 | Completed |
| NCT00596466 | Phase 3 | Completed |
| NCT00553280 | Phase 3 | Completed |
| NCT01061697 | Approved | Completed |
| NCT00891397 | Pre-clinical | Terminated |
| NCT00448916 | Phase 3 | Completed |
| NCT00407797 | Approved | Terminated |
| NCT00424372 | Phase 3 | Completed |
| NCT00407511 | Approved | Completed |
| NCT00346034 | Phase 3 | Completed |
| NCT00843284 | Pre-clinical | Completed |
Competing Products
5 competing products in Post-Herpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| BMS-954561 + BMS-954561 + Placebo | Bristol Myers Squibb | Phase 2 | 35 |
| HSK16149,probenecid, cimetidine | Haisco Pharmaceutical Group | Phase 1 | 29 |